Conference icon

Conference

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.

Abstract:

The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Volume:
26
Issue:
22
Pages:
2788-2795
Publication date:
2008-05-05
DOI:
EISSN:
1873-2518
ISSN:
0264-410X
URN:
uuid:b7a4101b-d59c-4f2b-8956-bbcb57d3a8b5
Source identifiers:
67014
Local pid:
pubs:67014

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP